Ventana Biotech, Inc. (VNTA)

Ventana Biotech, Inc. (VNTA) — VMCI valuation read

Headline read on VNTA: VMCI of 41/100 versus a Financial Services sector median of 50. The 10-point below-median position is what makes Ventana Biotech, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on VNTA: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on VNTA: value (VNTA trades at 23.0x earnings, 28% above the Financial Services median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Financial Services median (10.0%)), and risk (net debt to EBITDA of 1.7x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Financial Services 12.0x baseline.

VNTA fell 2.7% over the trailing 7 days, with a -12.9% read on a 30-day basis.